Published in Int J Cancer on November 01, 2005
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol (2009) 2.88
Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol (2008) 2.65
Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg (2007) 2.37
Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg (2007) 2.30
Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. J Korean Med Sci (2010) 1.21
Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. Cancer Res Treat (2012) 1.14
Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int J Clin Oncol (2007) 1.08
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS One (2012) 1.08
Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer (2015) 1.07
DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors. Cancer Res (2013) 0.99
GEIS 2013 guidelines for gastrointestinal sarcomas (GIST). Cancer Chemother Pharmacol (2014) 0.99
Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Rev Anticancer Ther (2010) 0.95
The role of c-kit and imatinib mesylate in uveal melanoma. J Carcinog (2005) 0.91
Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate. Ther Clin Risk Manag (2008) 0.90
Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective. World J Surg Oncol (2008) 0.90
Updates on the management of gastrointestinal stromal tumors. Surg Oncol Clin N Am (2012) 0.89
Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. Oncologist (2015) 0.87
A case and literature review of complicated gastrointestinal stromal tumors. Gastroenterol Hepatol (N Y) (2008) 0.85
Pathologic complete response confirmed by surgical resection for liver metastases of gastrointestinal stromal tumor after treatment with imatinib mesylate. World J Gastroenterol (2008) 0.83
Metastasectomy for gastrointestinal stromal tumors. J Surg Oncol (2013) 0.83
Complete pathological response to Imatinib mesylate in an extraintestinal gastrointestinal stromal tumor. Int J Surg Case Rep (2014) 0.82
Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib. Oncotarget (2016) 0.81
Inhibition of KIT-glycosylation by 2-deoxyglucose abrogates KIT-signaling and combination with ABT-263 synergistically induces apoptosis in gastrointestinal stromal tumor. PLoS One (2015) 0.81
Considering the role of radiation therapy for gastrointestinal stromal tumor. Onco Targets Ther (2014) 0.80
All-trans retinoic acid inhibits KIT activity and induces apoptosis in gastrointestinal stromal tumor GIST-T1 cell line by affecting on the expression of survivin and Bax protein. J Exp Clin Cancer Res (2010) 0.80
The embryonic Brachyury transcription factor is a novel biomarker of GIST aggressiveness and poor survival. Gastric Cancer (2015) 0.80
Surgical second-look in high risk gastrointestinal stromal tumor of small intestine: A case report. Int J Surg Case Rep (2012) 0.79
Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors. Ther Adv Med Oncol (2012) 0.79
Pathologic complete response with neoadjuvant imatinib for locally advanced pelvic GIST. Int J Clin Oncol (2010) 0.78
Rare cystic liver lesions: a diagnostic and managing challenge. World J Gastroenterol (2013) 0.77
Targeting Disease Persistence in Gastrointestinal Stromal Tumors. Stem Cells Transl Med (2015) 0.77
RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor. Oncotarget (2016) 0.75
Preoperative imatinib treatment in patients with advanced gastrointestinal stromal tumors: patient experiences and systematic review of 563 patients. Int Surg (2015) 0.75
Gastrointestinal stromal tumor of the stomach with axillary lymph node metastasis: A case report. World J Gastroenterol (2017) 0.75
CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib. Sci Rep (2016) 0.75
Successful treatment of bleeding large duodenal gastrointestinal stromal tumour in a patient under dual antiplatelet therapy after recent drug-eluting coronary stent implantation. BMJ Case Rep (2014) 0.75
Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg (2012) 19.78
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol (2009) 5.57
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol (2005) 5.19
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol (2004) 5.12
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA (2012) 5.00
ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: results of a multicenter analysis. World J Surg (2014) 3.60
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA (2013) 3.46
Right-liver living donor transplantation for decompensated end-stage liver disease. Liver Transpl (2002) 2.86
Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging (2009) 2.67
Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology (2010) 2.60
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Gastric Cancer (2013) 2.05
False-positive FDG PET uptake--the role of PET/CT. Eur Radiol (2005) 1.97
Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int (2008) 1.95
MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol (2009) 1.92
Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc Res (2003) 1.91
Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol (2011) 1.89
The White test: a new dye test for intraoperative detection of bile leakage during major liver resection. Arch Surg (2008) 1.86
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res (2013) 1.84
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis (2002) 1.80
Adverse blood transfusion outcomes: establishing causation. Transfus Med Rev (2011) 1.72
Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol (2007) 1.71
The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol (2008) 1.71
Primary malignant sarcomas of the heart and great vessels in adult patients--a single-center experience. Oncologist (2007) 1.63
High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol (2009) 1.62
Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol (2007) 1.59
Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res (2006) 1.57
Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med (2012) 1.53
Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-α and melphalan. J Surg Oncol (2011) 1.51
Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol (2004) 1.49
Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res (2005) 1.49
Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematol (2005) 1.48
Unknown primary tumors: detection with dual-modality PET/CT--initial experience. Radiology (2004) 1.48
A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. Proc Natl Acad Sci U S A (2009) 1.47
Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience. Onkologie (2008) 1.45
MR-based attenuation correction for torso-PET/MR imaging: pitfalls in mapping MR to CT data. Eur J Nucl Med Mol Imaging (2008) 1.42
Guidelines for the treatment of postmenopausal osteoporosis for general practitioners. Aust Fam Physician (2002) 1.42
Raf kinase inhibitors in oncology. Onkologie (2005) 1.41
Recurrent high-grade leiomyosarcoma with heterologous osteosarcomatous differentiation. Virchows Arch (2005) 1.40
First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). J Cancer Res Clin Oncol (2014) 1.40
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Minimally invasive versus open esophagectomy: meta-analysis of outcomes. Dig Dis Sci (2010) 1.35
Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging (2006) 1.32
Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging (2003) 1.31
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis (2002) 1.31
Right living donor liver transplantation: an option for adult patients: single institution experience with 74 patients. Ann Surg (2003) 1.31
Achalasia: will genetic studies provide insights? Hum Genet (2010) 1.30
Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA (2006) 1.29
Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med (2008) 1.28
Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation (2002) 1.27
Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med (2004) 1.27
Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol (2013) 1.27
68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med (2011) 1.27
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol (2007) 1.26
Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol (2004) 1.26
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood (2003) 1.23
Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer (2005) 1.22
Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood (2008) 1.21
Living donor liver transplantation for hepatocellular carcinoma: a single-center preliminary report. Liver Transpl (2006) 1.20
[18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol (2008) 1.20
Comparison between minimally invasive video-assisted thyroidectomy and conventional thyroidectomy: is there any evidence-based information? Thyroid (2008) 1.19
High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome. Breast Cancer Res (2005) 1.19
Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI. Eur J Radiol (2013) 1.19
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res (2009) 1.18
Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol (2003) 1.17
Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging (2010) 1.17
Visceral artery aneurysms: Incidence, management, and outcome analysis in a tertiary care center over one decade. Eur Radiol (2015) 1.16
Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis. Liver Int (2010) 1.12
Appropriateness of allogeneic red blood cell transfusion: the international consensus conference on transfusion outcomes. Transfus Med Rev (2011) 1.12
Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition. Arch Dermatol (2008) 1.11
Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol (2010) 1.10
The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs (2005) 1.10
Three-dimensional delayed gadolinium-enhanced magnetic resonance imaging of hip joint cartilage at 3T: a prospective controlled study. Eur J Radiol (2012) 1.09
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS One (2012) 1.08
Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT. J Surg Oncol (2008) 1.08
Multicenter comparison of calibration and cross calibration of PET scanners. J Nucl Med (2002) 1.07
Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol (2004) 1.07
Positron emission tomography/computed tomography--imaging protocols, artifacts, and pitfalls. Mol Imaging Biol (2004) 1.07
Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma (2006) 1.06
Peripheral neuropathy: assessment of proximal nerve integrity by diffusion tensor imaging. Muscle Nerve (2013) 1.06
Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group. Cancer Imaging (2012) 1.05
Dual-energy-CT of hypervascular liver lesions in patients with HCC: investigation of image quality and sensitivity. Eur Radiol (2010) 1.05
Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: a systematic review. World J Gastroenterol (2013) 1.05
Secondary rise in blood pressure after renal denervation. Lancet (2012) 1.04
Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood (2007) 1.04
MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy. Eur Radiol (2014) 1.04
Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach? Dig Dis Sci (2008) 1.03
The two-incision, minimally invasive approach in the treatment of acetabular fractures. J Orthop Trauma (2013) 1.03